Infinimmune is a biotechnology company based in Alameda, California that develops antibody therapeutics sourced directly from the human immune system. Its discovery approach combines Complete Human immunosequencing, the Anthrobody library-on-B-cell platform, and the GLIMPSE antibody language model to identify, characterize, and optimize fully paired human antibodies across a large set of validated targets.
The company advances an internal pipeline of antibody programs in immunology indications including atopic dermatitis, IgA nephropathy, and ulcerative colitis, and extends its reach through pharma partnerships, including multi-target discovery collaborations with Merck and Immunome. Infinimmune was founded by scientists from 10x Genomics, Pacific Biosciences, and the Broad Institute, and is backed by investors including Playground Global, Pear VC, Regeneron Ventures, and RA Capital Management.
